Furthermore, 5–6% of individuals with prostate cancer exhibit amplification of the KDM5B copy number, and less than 1% of them show the heterozygous deletion of KDM5B [21,22,23,24,28,38]. Here, KDM5B is linked to prostate carcinoma.